{"prompt": "['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', 'If there is an agreed alternative explanation for the ALT or AST and TBL elevations, a', 'determination of whether the alternative explanation is an AE will be made and subsequently', 'whether the AE meets the criteria for a SAE:', 'If the alternative explanation is not an AE, record the alternative explanation on the', 'appropriate CRF', 'If the alternative explanation is an AE/SAE, record the AE /SAE in the CRF', 'accordingly and follow the AZ standard processes', 'If it is agreed that there is no explanation that would explain the ALT or AST and TBL', 'elevations other than the IMP:', \"Report an SAE (report term 'Hy's Law') according to AstraZeneca standard\", 'processes.', '-', 'The \"Medically Important\\' serious criterion should be used if no other serious', 'criteria apply', '-', 'As there is no alternative explanation for the HL case, a causality assessment of', \"'related' should be assigned.\", 'If, there is an unavoidable delay, of over 3 weeks, in obtaining the information necessary to', 'assess whether or not the case meets the criteria for HL, then it is assumed that there is no', 'alternative explanation until such time as an informed decision can be made:', \"Report an SAE (report term 'Potential Hy's Law') applying serious criteria and\", 'causality assessment as per above', 'Continue follow-up and review according to agreed plan. Once the necessary', 'supplementary information is obtained, repeat the review and assessment to', 'determine whether HL criteria are met. Update the SAE report according to the', 'outcome of the review', \"Actions Required When Potential Hy's Law Criteria are Met Before and After Starting\", 'Study Treatment', 'This section is applicable to patients who meet PHL criteria on study treatment having', 'previously met PHL criteria at a study visit prior to starting study treatment.', 'At the first on study treatment occurrence of PHL criteria being met the Principal Investigator', 'will:', 'Determine if there has been a significant change in the patients\\' condition\"', 'compared with the last visit where PHL criteria were met#', '-', 'If there is no significant change no action is required', '87(93)', 'Printed on 3/25/202']['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', '-', 'If there is a significant change notify the AstraZeneca representative, who will', 'inform the central Study Team, then follow the subsequent process described in', \"Potential Hy's Law Criteria met of this Appendix\", '# A \"significant\\' change in the patient\\'s condition refers to a clinically relevant', 'change in any of the individual liver biochemistry parameters (ALT, AST or total', 'bilirubin) in isolation or in combination, or a clinically relevant change in', 'associated symptoms. The determination of whether there has been a significant', 'change will be at the discretion of the Principal Investigator, this may be in', 'consultation with the treating physician if there is any uncertainty.', \"Actions Required for Repeat Episodes of Potential Hy's Law\", 'This section is applicable when a patient meets PHL criteria on study treatment and has', 'already met PHL criteria at a previous on study treatment visit.', 'The requirement to conduct follow-up, review and assessment of a repeat occurrence(s) of', 'PHL is based on the nature of the alternative cause identified for the previous occurrence.', 'The Principal Investigator should determine the cause for the previous occurrence of PHL', 'criteria being met and answer the following question:', 'Was the alternative cause for the previous occurrence of PHL criteria being met', 'found to be the disease under study e.g. chronic or progressing malignant disease,', 'severe infection or liver disease, or did the patient meet PHL criteria prior to', 'starting study treatment and at their first on study treatment visit as described in', \"Actions Required When Potential Hy's Law Criteria are Met Before and After\", 'Starting Study Treatment?', \"If No: follow the process described in Potential Hy's Law Criteria met of this Appendix\", 'If Yes:', 'Determine if there has been a significant change in the patient\\'s condition\"', 'compared with when PHL criteria were previously met If there is no significant', 'change no action is required', 'If there is a significant change follow the process described in this Appendix', '# A \"significant\\' change in the patient\\'s condition refers to a clinically relevant', 'change in any of the individual liver biochemistry parameters (ALT, AST or total', 'bilirubin) in isolation or in combination, or a clinically relevant change in', 'associated symptoms. The determination of whether there has been a significant', 'change will be at the discretion of the Principal Investigator; this may be in', 'consultation with the treating physician if there is any uncertainty.', '88(93)', 'Printed on 3/25/202']\n\n###\n\n", "completion": "END"}